New combo therapy aims to control hard-to-treat colorectal and pancreatic cancers
NCT ID NCT03104439
First seen Jan 12, 2026 · Last updated May 14, 2026 · Updated 21 times
Summary
This study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) with radiation therapy can help control colorectal and pancreatic cancers that are either microsatellite stable (MSS) or MSI-high. About 84 adults with these cancers will receive the treatment. The main goal is to see how many patients achieve disease control (tumor shrinkage or stability).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.